Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Adrienne Howard"'
Autor:
Melissa M Singh, Adrienne Howard, Mary E Irwin, Yin Gao, Xiaolin Lu, Asha Multani, Joya Chandra
Publikováno v:
PLoS ONE, Vol 7, Iss 12, p e51611 (2012)
The BCR-ABL1 oncogene is a tyrosine kinase that activates many signaling pathways, resulting in the induction of chronic myeloid leukemia (CML). Kinase inhibitors, such as imatinib, have been developed for the treatment of CML; however, the terminal,
Externí odkaz:
https://doaj.org/article/ed0cff22051b49f38527f7a4e0f4f26c
Autor:
Kenneth R. Hess, Kristin L. Parkhurst, Deeksha Vishwamitra, Razelle Kurzrock, Filip Janku, Laura S. Angelo, Gerald Steven Falchook, Aung Naing, David S. Hong, Nizar M. Tannir, Mei Huang, Jennifer J. Wheler, Edward F. Jackson, Hesham M. Amin, Chaan S. Ng, Adrienne Howard, Kristie Lawhorn
Publikováno v:
Oncotarget, vol 5, iss 21
Oncotarget
Oncotarget
// Gerald S Falchook 1 , Jennifer J Wheler 2 , Aung Naing 2 , Edward F Jackson 3 , Filip Janku 2 , David Hong 2 , Chaan S Ng 4 , Nizar M Tannir 5 , Kristie N Lawhorn 6 , Mei Huang 2 , Laura S Angelo 7 , Deeksha Vishwamitra 8 , Kenneth Hess 9 , Adrien
Autor:
Jennifer J. Wheler, Siqing Fu, Sarina Anne Piha-Paul, David S. Hong, F. Diane Barber, Razelle Kurzrock, Apostolia Maria Tsimberidou, Gerald S. Falchook, Adrienne Howard, Aung Naing
Publikováno v:
Journal of Clinical Oncology. 30:2891-2896
Purpose Patients with advanced malignancies referred for early clinical trials have a short life expectancy. We designed this survey to ascertain the status of advance care planning in this population. Patients and Methods Patients who were seen in a
Autor:
Siqing Fu, Gerald S. Falchook, Razelle Kurzrock, Jennifer J. Wheler, Adrienne Howard, Kristen Price, David S. Hong, Joseph L. Nates, Diane Barber, Aung Naing, Sijin Wen
Publikováno v:
Journal of Clinical Oncology. 29:3547-3552
Purpose This study assessed outcomes of individuals with advanced cancer who required admission to an intensive care unit (ICU) after referral for an early clinical trial because they did not respond to conventional therapy. Patients and Methods Outc
Autor:
Hesham M. Amin, Joya Chandra, Yin Gao, Ralph B. Arlinghaus, Claudia P. Miller, Kechen Ban, Menashe Bar-Eli, Quan Lin, Mark F. Munsell, Xiaohong Leng, Adrienne Howard
Publikováno v:
Blood. 111:2904-2908
Chronic myelogenous leukemia (CML) invariably progresses to blast crisis, which represents the most proliferative phase of the disease. The BCR-ABL1 oncogene stimulates growth and survival pathways by phosphorylating numerous substrates, including va
Autor:
Siqing Fu, Sarina Anne Piha-Paul, Adrienne Howard, Dennis Tu, Gerald S. Falchook, David S. Hong, Lacey McQuinn, Jennifer J. Wheler, Filip Janku, Apostolia Maria Tsimberidou, Razelle Kurzrock, Aung Naing, Ralph Zinner
We conducted this retrospective study to identify reasons that patients referred to a phase I clinical trial failed to enroll or delayed enrollment onto the trial.Outcome analyses were conducted independently on data collected from electronic medical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79640038de2c67d50023546a29d3b19c
https://europepmc.org/articles/PMC3868426/
https://europepmc.org/articles/PMC3868426/
Autor:
Xiaolin Lu, Adrienne Howard, Joya Chandra, Yin Gao, Melissa M. Singh, Asha S. Multani, Mary E. Irwin
Publikováno v:
PLoS ONE
PLoS ONE, Vol 7, Iss 12, p e51611 (2012)
PLoS ONE, Vol 7, Iss 12, p e51611 (2012)
The BCR-ABL1 oncogene is a tyrosine kinase that activates many signaling pathways, resulting in the induction of chronic myeloid leukemia (CML). Kinase inhibitors, such as imatinib, have been developed for the treatment of CML; however, the terminal,
Autor:
Razelle Kurzrock, Jane Li, Kristine Dice, David M. Gershenson, Adrienne Howard, Robert L. Coleman, Charles F Levenback, Gordon B. Mills, Judith K. Wolf, Robert C. Bast, Edward F. Jackson, Chaan S. Ng, Kevin R. Coombes, Siqing Fu, John J. Kavanagh, Zhenlin Ju, Bryan T. Hennessy, Vikas Kundra, Anil K. Sood, Yang Li, Katherine Stemke-Hale, Edward N. Atkinson, Mary D. Dyer, Maurie Markman
Publikováno v:
Gynecologic oncology. 126(1)
Objectives On the basis of reversal of taxane resistance with AKT inhibition, we initiated a phase I trial of the AKT inhibitor perifosine with docetaxel in taxane and platinum-resistant or refractory epithelial ovarian cancer. Methods Patients with
Signaling initiated by the BCR-ABL1 kinase causes chronic myelogenous leukemia (CML). Recently, we reported that expression of Fyn, a Src kinase, is heightened in CML cells and patient specimens and confers in vitro and in vivo proliferative advantag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd950047f3dab610fdd0ae9698ecdb73
https://europepmc.org/articles/PMC2652262/
https://europepmc.org/articles/PMC2652262/
Publikováno v:
Cancer chemotherapy and pharmacology. 65(1)
This study assessed the role of oxidative stress and loss of glutathione in ABT-737-induced apoptosis. Jurkat human acute lymphocytic leukemia cells and HeLa cells transfected with a tet-regulated Bcl-2 expression system were treated with ABT-737 or